Intra-Cellular Therapies, Inc.
—- Market cap
- —
- Debt
- +$216.05M
- Cash
- −$306.95M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $1.22B · View financials
Decision snapshot: ITCI stock price vs CBRL: inconclusive — current versus $2.24 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CBRL's multiple
Implied fair value · at ITCI's multiple
Needs ITCI P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ITCI FY 2024 (ended Dec 31, 2024) · CBRL FY 2025 (ended Aug 1, 2025). Fiscal years are not aligned.
Trendline
11 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 72% equity / 28% debt · EV / Revenue 0.48x · EV / EBITDA 6.98x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Intra-Cellular Therapies, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Cracker Barrel Old Country Store, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
1.05x
Net debt / EBITDA
Leverage against operating earnings
1.23x
1.86x
Cash and equivalents
Liquid reserves on the balance sheet
$306.95M
$39.64M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ITCI vs SUPN
ACADIA PHARMACEUTICALS INC
ITCI vs ACAD
Vanda Pharmaceuticals Inc.
ITCI vs VNDA
Sage Therapeutics, Inc.
ITCI vs SAGE
DARDEN RESTAURANTS INC
ITCI vs DRI
Bloomin' Brands, Inc.
ITCI vs BLMN
Dine Brands Global, Inc.
ITCI vs DIN
BRINKER INTERNATIONAL, INC
ITCI vs EAT
Texas Roadhouse, Inc.
ITCI vs TXRH
$216.05M
$484.64M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.